30 closest matches · ranked by relevance
Japanese Encephalitis
Primary: Percentage of Participants With Demonstrated Seropositivity for Japanese Encephalitis (JE) Neutralizing Antibodies — 98.0; 99.3; 100.0; 100.0 percentage of participants
Encephalitis, Japanese B
Primary: Seroconversion Rate After Primary Vaccination — 100 percentage of seroconversion
Japanese Encephalitis
Primary: Number and Percentage of Subjects With Demonstrated Seropositivity for Japanese Encephalitis (JE) Neutralizing Antibodies — 14; 243; 233; 24 Participants
Japanese Encephalitis · Varicella
Primary: Percentage of Participants With JE Seroprotection Before and Following a Dose of Live Attenuated JE-CV — 80.3; 0; 96.2; 15.4 Percentage of participants
Japanese Encephalitis
Primary: Percentage of Subjects With Seroconversion Rate (SCR) ≥ 1:10 Anti-JEV Neutralizing Antibody Titer (PRNT) — 81.8 percentage of subjects
Encephalitis · Japanese Encephalitis
Primary: Number of Participants With Japanese Encephalitis Seroconversion After Vaccination With One Dose of Either Japanese Encephalitis Chimeric Vaccine (JE-CV) or Japanese…
Encephalitis
Primary: Rate of Subjects With Serious Adverse Events and Medically Attended Adverse Events Until Day 56 After First Vaccination — 16.1; 14.2; 38.2; 42.2 percentage of…
Japanese Encephalitis · Japanese Encephalitis Vaccine
Primary: Change of T Lymphocyte Responses to Live Attenuated JE SA-14-14-2 Vaccine at Week 2. — 34 IFNγ SFC/million PBMC
Japanese Encephalitis
Primary: Number of Participants Who Seroconverted to the Respective Homologous JE Vaccine Strain Up to 28 Days After the First Active Vaccination With Either ChimeriVax™-JE or…
Japanese Encephalitis
Primary: Number of Participants With Japanese Encephalitis (Homologous Virus) Seroconversion Following Either ChimeriVax™-JE or JE-Vax® Vaccination — NA; 324; 273; 343 Participants
Japanese Encephalitis
Primary: SCR (Seroconversion Rate)of IC51 Compared to JE-VAX at Day 56 — 96.4; 93.6 percentage of participants
Encephalitis, Japanese B
Primary: Percentage of Participants With Seroprotection for Measles 4 Weeks After Vaccination — 1.1; 0.0; 0.0; 88.6 percentage of participants
Encephalitis · Japanese Encephalitis
Primary: Number of Participants Reporting Treatment Related Adverse Events Post Vaccination With Either ChimeriVax™-JE or a Placebo — 90; 365; 69; 297 Participants
Japanese Encephalitis · Japanese Encephalitis Virus Disease
Primary: Percentage of Participants With Seroconversion to Japanese Encephalitis Chimeric Virus Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis…
Encephalitis · Japanese Encephalitis
Primary: Percentage of Participants With Japanese Encephalitis Seroprotection Following a Single Dose of JE-CV — 2.6; 100.0; 88.2; 90.0 Percentage of participants
Japanese Encephalitis
Primary: Number of Participants With Treatment Emergent Adverse Events Following Vaccination With Either ChimeriVax™ JE or JE Inactivated Mouse Brain Derived Vaccine — 2; 2; 1; 0…
Japanese Encephalitis
Primary: SCR (Seroconversion Rate) at Day 56 — 41.2; 97.3; 25.6 percentage of participants — p=>0.99
Encephalitis, Japanese B
Primary: Measles Seropositivity at 24 and 36 Months — 98.92; 95.75; 94.37; 94.62 percentage of participants seropositive
Japanese Encephalitis
Primary: Safety and Tolerability up to Day 56 — 58.9; 56.6 percentage of participants with AEs
Japanese Encephalitis
Primary: Number of Participants Who Seroconverted to the Respective Homologous JE Vaccine Strain, 28 Days After Completion of the Primary Immunization Schedule With One of 3…
Encephalitis
Primary: Rate of Subjects With Serious Adverse Events (SAEs) and Medically Attended AEs up to Day 56 After the First Vaccination — 33.3; 20.7; 3.4 percentage of participants
Japanese Encephalitis
Primary: Seroconversion Rate — 98.5 percent
Japanese Encephalitis
Primary: Long Term Immunogenicity of IC51 Vaccine 24 Months After the Primary Vaccination — 56; 7; 5 percentage of participants
Encephalitis
Primary: Change From Baseline in Geometric Mean Titers Against the Japanese Encephalitis Chimeric Virus at 28 Days Post Vaccination — 9144 titers
Japanese Encephalitis
Primary: SCRs (Seroconversion Rate) as Defined by Percentage of Subjects With Plaque Reduction Neutralization Test Titers of>1:10 at 1 Month After the Booster Dose — 100; 100…
Japanese Encephalitis
Primary: Primary: Plasmablast Percentage of Total B Cells at 7 Days Post Vaccine — 1.36; 1.96; 1.69 percent plasmablasts of B cells
Encephalitis, Japanese · Measles · Mumps
Primary: Percentage of Participants With Measles Seropositivity 56 Days Post-vaccination — 98.1; 98.0 percentage of participants
Rabies · Japanese Encephalitis
Primary: Percentages of Subjects With RVNA Concentrations ≥0.5 IU/mL At 7 Days After Last Active Vaccination — 100; 100 Percentages of subjects
Japanese Encephalitis
Primary: Number/Percentage of Subjects With Demonstrated Seroprotection — 126; 160; 154; 164 Participants — p=<0.05
Japanese Encephalitis · Measles · Mumps
Primary: Percentage of Participants With Seroconversion to Vaccine Antigens Following Concomitant Administration of Japanese Encephalitis Chimeric Virus Vaccine (JECV) and MMR or…